Due to the prevalence of the PI3K‐Akt pathway in tumorigenesis and its criticality to the development of ccRCC, the PI3K isoform inhibitors, AKTs, mTORs, and other components of the pathway were being actively pursued for targeted cancer therapies [28]. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.